WO2003091698A3 - Cetp genetic markers for statin-specific changes in hdl cholesterol - Google Patents

Cetp genetic markers for statin-specific changes in hdl cholesterol Download PDF

Info

Publication number
WO2003091698A3
WO2003091698A3 PCT/US2003/013346 US0313346W WO03091698A3 WO 2003091698 A3 WO2003091698 A3 WO 2003091698A3 US 0313346 W US0313346 W US 0313346W WO 03091698 A3 WO03091698 A3 WO 03091698A3
Authority
WO
WIPO (PCT)
Prior art keywords
statin
cetp
genetic markers
hdl cholesterol
specific changes
Prior art date
Application number
PCT/US2003/013346
Other languages
French (fr)
Other versions
WO2003091698A2 (en
Inventor
Carlos D Brain
Bradley J Dain
Richard S Judson
Chad Messer
Carol R Reed
Original Assignee
Genaissance Pharmaceuticals
Carlos D Brain
Bradley J Dain
Richard S Judson
Chad Messer
Carol R Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals, Carlos D Brain, Bradley J Dain, Richard S Judson, Chad Messer, Carol R Reed filed Critical Genaissance Pharmaceuticals
Priority to AU2003228761A priority Critical patent/AU2003228761A1/en
Publication of WO2003091698A2 publication Critical patent/WO2003091698A2/en
Publication of WO2003091698A3 publication Critical patent/WO2003091698A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

Genetic markers in the CETP gene associated with statin-specific changes in HDL cholesterol after statin treatment are disclosed. Compositions and methods for detecting and using these CETP genetic markers in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising a statin composition approved for treating patients having one of these CETP haplotypes, methods and kits for predicting the response of an individual to a given statin treatment based on their haplotype profile, and methods for treating individuals with hyperlipidemia based on their haplotype profile.
PCT/US2003/013346 2002-04-26 2003-04-28 Cetp genetic markers for statin-specific changes in hdl cholesterol WO2003091698A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003228761A AU2003228761A1 (en) 2002-04-26 2003-04-28 Cetp genetic markers for statin-specific changes in hdl cholesterol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37579102P 2002-04-26 2002-04-26
US60/375,791 2002-04-26

Publications (2)

Publication Number Publication Date
WO2003091698A2 WO2003091698A2 (en) 2003-11-06
WO2003091698A3 true WO2003091698A3 (en) 2005-04-21

Family

ID=29270700

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/013346 WO2003091698A2 (en) 2002-04-26 2003-04-28 Cetp genetic markers for statin-specific changes in hdl cholesterol
PCT/US2003/013288 WO2003091277A2 (en) 2002-04-26 2003-04-28 Haplotypes of the cetp gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013288 WO2003091277A2 (en) 2002-04-26 2003-04-28 Haplotypes of the cetp gene

Country Status (2)

Country Link
AU (2) AU2003239189A1 (en)
WO (2) WO2003091698A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUIVENHOVEN ET AL: "The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis", THE NEW ENGLAND JOURNAL OF MEDICINE, January 1998 (1998-01-01), pages 86 - 93, XP002069666 *
MAITLAND-VAN DER ZEE A-H. ET AL: "Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors", ATHEROSCLEROSIS, vol. 163, 2002, pages 213 - 222, XP002904001 *
VAN VENROOIJ ET AL: "Common CETP polymorphisms modify the efficacy of statin therapy in diabetes mellitus type 2 patients with diabetic dyslipidemia - abstract number 855", CIRCULATION, vol. 104, no. 17, October 2001 (2001-10-01), pages II - 177, XP002904029 *

Also Published As

Publication number Publication date
AU2003228761A8 (en) 2003-11-10
WO2003091277A2 (en) 2003-11-06
WO2003091277A3 (en) 2005-04-14
AU2003239189A8 (en) 2003-11-10
AU2003239189A1 (en) 2003-11-10
AU2003228761A1 (en) 2003-11-10
WO2003091698A2 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
AU2003299817A1 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2004053062A3 (en) Bentgrass event asr-368 and compositions and methods for detection thereof
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2005059108A3 (en) Gene expression profiles and methods of use
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
AU2003223367A1 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2003070082A3 (en) Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
WO2005072152A3 (en) Apoc1 genetic markers associated with age of onset of alzheimer's disease
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2005059105A3 (en) Cdk5 genetic markers associated with galantamine response
WO2004033710A3 (en) Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
WO2007095287A3 (en) Protective complement proteins and age-related macular degeneration
WO2005072150A3 (en) Ldlr genetic markers associated with age of onset of alzheimer's disease
WO2004110365A3 (en) Liver related disease compositions and methods
WO2003091698A3 (en) Cetp genetic markers for statin-specific changes in hdl cholesterol
WO2005037204A3 (en) Ntrk1 genetic markers associated with age of onset of alzheimer's disease
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2004003167A3 (en) Gucy1b2 genetic markers for ldl cholesterol response to statin therapy
WO2005042706A3 (en) Ephx2 genetic markers associated with galantamine response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP